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Multiple sclerosis (MS) susceptibility is influenced by a combination of genetic factors and environmental exposures. CD4+ T cells have long been favoured as the most important immune cell subset in the pathogenesis of disease, but there is increasing evidence that CD8+ T cells play a substantial role in central nervous system damage (reviewed in \[[@CR1]\]).

Despite several large genome-wide association studies (GWAS), there remains a large proportion of unexplained heritability in terms of MS risk. Epigenetics can influence the genome without changes to the DNA sequence. Environmental exposures such as smoking and vitamin D levels have been demonstrated to modify epigenetic mechanisms, providing a plausible link between environmental factors and disease \[[@CR2], [@CR3]\]. One such epigenetic mechanism is DNA methylation, which is the addition of a methyl group to CpG dinucleotides. We, and others, have used genome-wide DNA methylation technologies to assess differentially methylated regions (DMRs) of CD4+ T cells in MS patients compared to healthy controls \[[@CR4]--[@CR6]\]. We found a striking methylation signal located on chromosome 6p21 with a peak signal at HLA-DRB1, which remained after controlling for background SNP effects, as well as 55 non-HLA CpGs that localise to genes previously linked with MS.

In an effort to determine if these previously identified DMRs were specific to CD4+ T cells, we performed a genome-wide methylation study of CD8+ T cells using the same cohort, workflow and data analysis as described in our previous study \[[@CR5]\]. Briefly, DNA from total CD8+ T cells was extracted from 30 MS patients and 28 healthy age- and sex-matched controls. The DNA was bisulphite-converted and hybridised to Illumina 450K arrays. Raw fluorescence data were processed using a combination of R/Bioconductor and custom scripts of a total of 442,672 probes representing individual CpG sites that passed quality control (QC) steps. These CpGs were analysed by statistical modelling of methylation levels (*β* values) between MS cases and controls.

Figure [1](#Fig1){ref-type="fig"} shows the genome-wide distribution of differential methylation scores for all CpG sites that passed the nominal *p* value cut-off of 0.05. We conducted a stepwise prioritisation strategy to extract the most robust CpG loci associated with MS. Based on the criteria of (i) FDR *p* \< 0.05 and (ii) *Δ*~meth~ ≥ ± 0.1 thresholds, 111 CpGs were extracted. To filter out potential effects of gender and treatment, we performed a subgroup analysis of the methylation statistics as previously described \[[@CR5]\]. This process reduced the number of associated CpG sites down to a core panel of 79 (Table [1](#Tab1){ref-type="table"}).Fig. 1A genome-wide differential methylation plot based on sites passing a nominal *p* value of 0.05*. Data points outside* the circle represent increased methylation in multiple sclerosis (MS) patients compared to controls (i.e. Δ~meth~)~,~ whereas *points inside* the circle represent methylation in the MS groupTable 1MS-associated CpGs in CD8+ T cellsProbe ID^a^CHR^b^PositionGene^c^FeatureMedian (case)Median (control)*Δ* ~meth~ ^d^*p* value^e^cg034317382140031295ERG5′UTR0.810.680.130.004033cg120260951949468461FTLTSS2000.300.49−0.180.004033cg262281231473392919DCAF4TSS2000.090.20−0.110.004033cg104780351380919503-0.750.640.110.004033cg0447498810131770171-0.340.46−0.110.03549cg251523482250946712NCAPH21st exon0.300.47−0.170.03549cg08206623112907334CDKN1CTSS15000.290.44−0.150.004033cg137386159109624741ZNF462TSS15000.180.31−0.130.004033cg015252442239548611CBX7TSS2000.140.24−0.100.004033cg127021651295228136MIR492TSS2000.650.540.110.004033cg0644354210100206752HPS1TSS2000.140.25−0.110.03549cg003801726148663585SASH1TSS2000.210.33−0.120.03549cg190951876108437051-0.170.31−0.140.03549cg04488145346899455MYL33′UTR0.830.730.110.03549cg030272412049620453KCNG13′UTR0.500.320.180.004033cg117009851082127205DYDC23′UTR0.850.740.110.03549cg078861425126793022MEGF103′UTR0.590.460.130.03549cg181831632171574141SP53′UTR0.120.26−0.140.03549cg011814151216757954LMO35′UTR0.220.36−0.140.03549cg101438111216757985LMO35′UTR0.120.22−0.100.03549cg232741231229478617C1orf965′UTR0.100.22−0.120.004033cg0009527651068111SLC12A7Body0.770.630.150.004033cg0344755712273735MORN1Body0.800.700.100.03549cg027458471747075880IGF2BP1Body0.170.31−0.130.03549cg094067951164019655PLCB3Body0.250.38−0.130.000358cg180162881395834131ABCC4Body0.470.320.150.000358cg144863462102000131CREG2Body0.780.660.120.03549cg2193724414103406412CDC42BPBBody0.750.610.140.03549cg118118402234669166UGT1A10Body0.840.720.120.03549cg25756617143734917TMEM125TSS15000.690.580.110.03549cg037689161049813307ARHGAP22TSS2000.300.43−0.140.004033cg065247571372441523DACH1TSS2000.250.35−0.110.03549cg0316874911124413574OR8B12TSS2000.820.680.140.03549cg212760229136390236TMEM8CTSS2000.740.610.130.004033cg098515968143545214BAI1TSS2000.600.490.110.03549cg25296222112037173-0.760.650.110.03549cg0087853312848864-0.720.620.110.000358cg036127001718970610-0.640.520.120.004033cg03310594722704316-0.820.690.132.34E-05cg058546941461123243-0.120.22−0.100.000358cg123844991589949617-0.190.31−0.110.004033cg22509113291777482-0.410.51−0.100.004033cg104950841596889416-0.240.36−0.120.004033cg1800801913100641646-0.100.23−0.120.03549cg1209377513112548065-0.150.26−0.110.000358cg1278732310119494959-0.160.27−0.110.004033cg227928621467827087EIF2S11st exon0.230.38−0.150.004033cg089695321099790438CRTAC11st exon0.050.15−0.100.004033cg181850283154042079DHX361st exon0.300.41−0.110.000358cg230599651950655862C19orf413′UTR0.810.700.110.004033cg0219267881495185DLGAP25′UTR0.780.680.110.004033cg02976009632068226TNXB5′UTR0.710.590.120.03549cg18073471481119198PRDM85′UTR0.180.29−0.110.03549cg009458107814391HEATR2Body0.670.560.110.03549cg0487561442008706WHSC2Body0.800.690.102.34E-05cg2692062717319248CAMTA1Body0.750.630.120.004033cg26647242230040525ALKBody0.780.670.110.004033cg046058162062092443KCNQ2Body0.830.710.120.004033cg109440632120233706SCTRBody0.580.460.120.004033cg145952697151216272RHEBBody0.140.24−0.102.34E-05cg237201255177097760LOC202181Body0.850.730.120.004033cg02047661351976883RRP9TSS15000.640.520.110.004033cg079255491252828840KRT75TSS15000.750.630.120.03549cg066970941754911185DGKETSS15000.160.28−0.120.03549cg187896631242688591PLD5TSS15000.090.20−0.110.03549cg034685411489029199ZC3H14TSS2000.170.30−0.130.004033cg135262218987389-0.790.690.110.004033cg03313895424803042-0.650.540.100.03549cg19442593226252851-0.850.740.110.004033cg04851089628953923-0.390.54−0.150.004033cg24520975631651362-0.860.750.110.03549cg019320762147394659-0.180.30−0.122.34E-05cg17555825576924190-0.160.26−0.100.03549cg231547811580634195-0.810.690.120.004033cg007925136100066698-0.340.47−0.140.03549cg2370856914106058450-0.630.510.132.34E-05cg0957998912110685438-0.810.710.100.03549cg1207766412125145446-0.780.640.140.000358cg248240822133030701-0.240.35−0.110.000358Dash indicates intergenic*UTR* untranslated region, *TSS* transcription start site^a^Probe ID on 450K chip^b^Chromosome^c^Gene annotated to probe^d^Differential-methylated score^e^ *p* value for specified probe in CD8+ T cells

Of the 79 CpGs showing differential methylation in MS patients after filtering, all resided outside the MHC locus on chr 6p21. Of these, 27 were intergenic (34 %), have no gene association, or map to genes of unknown function. Of the remaining 52 loci, 26 % are promoter associated, 9 % are in the 5′UTR, 5 % are in the 1st exon, 20 % are in gene bodies and 8 % are in the 3′UTR. Interestingly, none of these CpGs maps to genes that have previously been reported to have a relationship with MS \[[@CR7], [@CR8]\]. There was no overlap between these results and our previous results, and, unlike in CD4+ T cells, there was no gene that contained multiple differentially methylated sites. *MORN1* has a single hypermethylated CpG in both CD4+ and CD8+ T cells; however, it was a different site in each study, making it unlikely that this is a significant finding. Our observations are consistent with the recent study by Bos et al., who also identified minimal overlap between the methylation profiles of CD4+ and CD8+ T cells of MS patients \[[@CR4]\].

Using GSEA with WebGestalt, our patient cohort did not have prominent pathways in the KEGG Pathway analysis or disease association analysis. The most significant promoter associated with differential methylation was the ferritin light chain (*FTL*) gene. The MS cohort displayed decreased methylation at this CpG locus compared to controls. The gene's biological function is cation transport. One of the statistically significant genes, *ERG* (ETS-related gene)*,* had a single hypermethylated CpG in the MS cohort compared to controls. *ERG* is a member of the transcription factor family involved in activities such as cell proliferation, differentiation, apoptosis and inflammation. *FTL* is a component of ferritin, and defects in this subunit are associated with other neurodegenerative diseases where mutations result in accumulation of iron in the brain \[[@CR9]\]. Relapsing--remitting multiple sclerosis (RRMS) patients have increased iron deposits in their grey matter as compared to healthy controls; thus, misregulation of *FTL* could be important in disease pathology \[[@CR10], [@CR11]\]. Mutations in *DCAF4* are associated with leucocyte telomere length, and there is evidence that shortened telomere length in leucocytes is associated with other neurodegenerative diseases, such as Parkinson and Alzheimer's disease \[[@CR12]--[@CR14]\]. In addition, one study found a shorted telomere length in primary progressive MS patients, but no correlation between RRMS and differing telomere length has been established \[[@CR15]\].

Interestingly, we did not see a cluster of differentially methylated CpGs within *HLA-DRB1* as seen in CD4+ T cells \[[@CR5]\]. It is well known that the HLA region is notoriously difficult to investigate with many molecular techniques due to increased genetic variation. To minimise the possibility that our observed methylation profile was due to the probes in this region not meeting QC, we used targeted pyrosequencing on available case and control DNA samples. This assay covered seven of the ten differentially methylated CpGs identified in our previous study, but due to high sequence variability, only five of the seven sites returned data. We calculated the median beta values across the five CpG sites using the K--S test. Results showed that the median methylation level in the cases (median = 3.6) and controls (median = 3.6) was not significantly different (*p* = 0.72). This supports a conclusion that this MS-related DMR at *HLA-DRB1* does not exist in CD8+ T cells but is unique to CD4+ T cells.

A recent study by Bos et al. (2015) also found no major effect loci or clusters of differentially methylated CpGs in the CD8+ T cells of MS patients. However, of the top 40 CpG sites, none overlaps with the top 79 sites found in our study. In addition, we found that approximately half the differentially methylated sites were hypermethylated. This is also in contrast to Bos et al., who found nearly 95 % of sites were hypermethylated in CD8+ T cells. Unlike Bos et al., we chose not to filter out probes that are known to contain SNPs. We reasoned that any false positive signals exclusively due to SNP effects would be subsequently identified by genotyping at the key loci. In support of this notion, pyrosequencing of the key *HLA-DRB1* locus did not alter our array-based findings. Additionally, we did not observe a signal at the *HLA-DRB1* locus in CD8+ T cells but did in CD4+ T cells, providing further support that SNPs are not influencing the findings at this locus.

One important consideration of our study is that the patients were being, or had been, treated with various immunomodulatory therapies at the time of recruitment. In particular, eight patients were being treated with fingolimod, which prevents CD4+ lymphocyte egress from lymphoid tissue. As part of our analysis, we stratified our case--control analysis based on treatment groups in an effort to determine whether overall differential methylation signal may be confounded. None of the patient treatment groups shows a distinct methylation signature, including fingolimod (data not shown), which supports the notion that the small number of treated patients in our cohort is not affecting our results. We do note that this does not necessarily mean that fingolimod is not acting on the methylome, but we can conclude that the small number of patients being treated with fingolimod in our study is not confounding the findings. Future studies will benefit from treatment-naïve patients or will be limiting the study to patients on a particular treatment group.

In this study, we identified 79 CpGs showing minor association with MS. None of these hits was observed in the CD4+ T cells from the same cohort, including the major CD4+ DMR at *HLA-DRB1*. All genome-wide DNA methylation studies to date have used relatively small sample sizes. This has resulted in identification of large-effect regions only. Large-scale studies are needed to identify minor-effect DMRs. Future studies should also examine the functional consequences of these changes through transcript analysis. Primarily, the results of this study highlight the need to focus on individual cell types when assessing DNA methylation associated with MS susceptibility.
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